Haruhito Azuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haruhito Azuma has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
- Akito Terai
10Department of Urology, Kurashiki Central Hospital, Kurashiki, Japan
12 shared publications - Hideaki Miyake
Division of Urology Kobe University Graduate School of Medicine Hyogo Japan
12 shared publications - Hiroji Uemura
Departments of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan
12 shared publications - Hiroyuki Nishiyama
Department of Urology, Faculty of Medicine University of Tsukuba Tsukuba Ibaraki Japan
12 shared publications - Junji Yonese
Department of Urology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan
12 shared publications - Masatoshi Eto
Department of Urology, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
12 shared publications
Latest Publications
- 26 October 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (10)
Real‐World Characteristics and Early Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma
Background: Enfortumab vedotin (EV) plus pembrolizumab (EVP) has become a standard first‐line regimen for unresectable locally advanced or metastatic urothelial carcinoma. Further characterization of clinical heterogeneity and toxicity may complement existing Japanese real‐world data. Methods: We conducted a multicenter prospective study across 11 Japanese institutions. Consecutive patients who initiated EVP for unresectable locally advanced or metastatic urothelial carcinoma between October 2024 and December 2025 were included. Patient characteristics, treatment exposure, response, adverse events, and short‐term survival outcomes were descriptively analyzed. Results: A total of 172 patients were included. Median age was 75 years, 73.8% had creatinine clearance < 60 mL/min, and 76.7% were classified as cisplatin‐unfit using modified Galsky criteria. Upper tract urothelial carcinoma accounted for 35.5% of cases. Median follow‐up was 7.1 months. Early EV dose reduction was recorded in 44.8% of patients, and discontinuation of at least one agent occurred in 61.0%. Among 158 response‐evaluable patients, the best overall objective response rate was 62.7% and the disease control rate was 82.3%; corresponding all‐treated estimates were 57.6% and 75.6%, respectively. Skin reaction was the most common adverse event, while pneumonitis was a major cause of treatment discontinuation. Conclusions: In Japanese real‐world practice, EVP was frequently used in older, renally impaired, cisplatin‐unfit patients. Response was clinically meaningful among evaluable patients, but interpretation requires caution because of short follow‐up and denominator‐dependent response estimates.
- 26 October 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (10)
Real‐World Characteristics and Early Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma
Background: Enfortumab vedotin (EV) plus pembrolizumab (EVP) has become a standard first‐line regimen for unresectable locally advanced or metastatic urothelial carcinoma. Further characterization of clinical heterogeneity and toxicity may complement existing Japanese real‐world data. Methods: We conducted a multicenter prospective study across 11 Japanese institutions. Consecutive patients who initiated EVP for unresectable locally advanced or metastatic urothelial carcinoma between October 2024 and December 2025 were included. Patient characteristics, treatment exposure, response, adverse events, and short‐term survival outcomes were descriptively analyzed. Results: A total of 172 patients were included. Median age was 75 years, 73.8% had creatinine clearance < 60 mL/min, and 76.7% were classified as cisplatin‐unfit using modified Galsky criteria. Upper tract urothelial carcinoma accounted for 35.5% of cases. Median follow‐up was 7.1 months. Early EV dose reduction was recorded in 44.8% of patients, and discontinuation of at least one agent occurred in 61.0%. Among 158 response‐evaluable patients, the best overall objective response rate was 62.7% and the disease control rate was 82.3%; corresponding all‐treated estimates were 57.6% and 75.6%, respectively. Skin reaction was the most common adverse event, while pneumonitis was a major cause of treatment discontinuation. Conclusions: In Japanese real‐world practice, EVP was frequently used in older, renally impaired, cisplatin‐unfit patients. Response was clinically meaningful among evaluable patients, but interpretation requires caution because of short follow‐up and denominator‐dependent response estimates.
- 21 October 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF14
Multiplex Immunofluorescence–Defined CXCL13-Associated TLS-like Niches Predict Outcomes in Bladder Cancer
Purpose: Spatially organized tertiary lymphoid structure (TLS)–like niches may provide prognostic and therapeutic information beyond individual immune mediators such as CXCL13 in bladder cancer. We evaluated the clinical and translational significance of multiplex immunofluorescence (mIF)–defined TLS-like structures (mTLS) in bladder cancer. Experimental Design: We analyzed 469 clinically annotated bladder cancer tumors using 41-plex mIF with the PhenoCycler platform. Bulk RNA sequencing, CIBERSORTx deconvolution, Cox modeling with CXCL13 as a continuous variable, and spatial neighborhood analysis were used to define mTLS-associated immune programs. Orthotopic bladder cancer mouse models treated with cisplatin and/or recombinant Cxcl13 followed by anti–PD-L1 blockade were analyzed by flow cytometry. Results: mTLS were identified in 22.2% of tumors and were not apparent on routine histopathology. mTLS positivity was associated with immune activation, improved survival, and favorable response patterns in a small PD-L1 blockade–treated subset. In Cox models, mTLS remained independently associated with outcomes, whereas continuous CXCL13 expression was not significant. Spatial profiling showed CXCL13/CXCR5-enriched B- and T-cell neighborhoods, including CXCL13-expressing and CXCR5-positive CD8+ T-cell subsets. In mouse models, cisplatin plus exogenous Cxcl13 was associated with lymphocyte infiltration, enrichment of CD8+ PD-1+ and CD8+ Cxcr5+ Cxcl13+ T-cell states, and sustained tumor control after PD-L1 blockade. Conclusions: mIF-defined mTLS identify a clinically relevant spatial immune architecture linked to favorable outcomes and therapeutic responsiveness in bladder cancer. These findings support prospective evaluation of mTLS as a spatial biomarker for risk stratification and treatment sequencing, with CXCL13/CXCR5 features interpreted as contextual companion markers rather than standalone determinants.
- 21 October 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF14
Multiplex Immunofluorescence–Defined CXCL13-Associated TLS-like Niches Predict Outcomes in Bladder Cancer
Purpose: Spatially organized tertiary lymphoid structure (TLS)–like niches may provide prognostic and therapeutic information beyond individual immune mediators such as CXCL13 in bladder cancer. We evaluated the clinical and translational significance of multiplex immunofluorescence (mIF)–defined TLS-like structures (mTLS) in bladder cancer. Experimental Design: We analyzed 469 clinically annotated bladder cancer tumors using 41-plex mIF with the PhenoCycler platform. Bulk RNA sequencing, CIBERSORTx deconvolution, Cox modeling with CXCL13 as a continuous variable, and spatial neighborhood analysis were used to define mTLS-associated immune programs. Orthotopic bladder cancer mouse models treated with cisplatin and/or recombinant Cxcl13 followed by anti–PD-L1 blockade were analyzed by flow cytometry. Results: mTLS were identified in 22.2% of tumors and were not apparent on routine histopathology. mTLS positivity was associated with immune activation, improved survival, and favorable response patterns in a small PD-L1 blockade–treated subset. In Cox models, mTLS remained independently associated with outcomes, whereas continuous CXCL13 expression was not significant. Spatial profiling showed CXCL13/CXCR5-enriched B- and T-cell neighborhoods, including CXCL13-expressing and CXCR5-positive CD8+ T-cell subsets. In mouse models, cisplatin plus exogenous Cxcl13 was associated with lymphocyte infiltration, enrichment of CD8+ PD-1+ and CD8+ Cxcr5+ Cxcl13+ T-cell states, and sustained tumor control after PD-L1 blockade. Conclusions: mIF-defined mTLS identify a clinically relevant spatial immune architecture linked to favorable outcomes and therapeutic responsiveness in bladder cancer. These findings support prospective evaluation of mTLS as a spatial biomarker for risk stratification and treatment sequencing, with CXCL13/CXCR5 features interpreted as contextual companion markers rather than standalone determinants.
- Open Access
NECTIN4 defines a subtype-dependent tumor state coupling enfortumab vedotin targetability to antitumor immunity in bladder cancer
SUMMARY: NECTIN4 is the target of enfortumab vedotin (EV), but its biological role in bladder cancer (BC) and its relationship to EV plus PD-1 blockade remain unclear. Integrating clinical multi-omics, spatial and single-cell immune profiling, and experimental models, we identify NECTIN4 as a subtype-dependent determinant of tumor state and antitumor immunity. In basal BC cells, NECTIN4 suppressed inflammatory and mesenchymal programs. Consistently, NECTIN4-high basal/squamous muscle-invasive BCs showed favorable survival, higher checkpoint inhibitor response rates, and a coordinated CD8+ T cell-inflamed microenvironment with no comparable associations in luminal papillary tumors. In orthotopic models, murine Nectin4 promoted CD8+ T cell-dependent tumor control, whereas human NECTIN4 conferred EV sensitivity. EV also attenuated NECTIN4-dependent TIGIT binding. Conversely, NECTIN4-low models were preferentially sensitive to HDAC inhibition. NECTIN4 therefore couples antibody-drug conjugate targetability to a subtype-specific tumor–immune state permissive for checkpoint blockade, whereas the NECTIN4-low state defines a distinct inflammatory-mesenchymal state with an alternative therapeutic vulnerability. eTOC blurb: Nishimura et al. show that NECTIN4, the target of enfortumab vedotin, defines subtype-dependent tumor–immune states in bladder cancer. In basal/squamous tumors, NECTIN4 restrains inflammatory-mesenchymal programs and marks a CD8-rich microenvironment linked to checkpoint inhibitor response, whereas NECTIN4-low models show preferential sensitivity to HDAC inhibition. HIGHLIGHTS: NECTIN4 is a subtype-dependent regulator of tumor state, not just an ADC target NECTIN4-high Ba/Sq tumors exhibit a coordinated CD8-inflamed microenvironment Nectin4 drives CD8 T cell-dependent tumor control in immunocompetent mice NECTIN4 couples EV targetability to a checkpoint-responsive immune context
Open AccessNECTIN4 defines a subtype-dependent tumor state coupling enfortumab vedotin targetability to antitumor immunity in bladder cancer
SUMMARY: NECTIN4 is the target of enfortumab vedotin (EV), but its biological role in bladder cancer (BC) and its relationship to EV plus PD-1 blockade remain unclear. Integrating clinical multi-omics, spatial and single-cell immune profiling, and experimental models, we identify NECTIN4 as a subtype-dependent determinant of tumor state and antitumor immunity. In basal BC cells, NECTIN4 suppressed inflammatory and mesenchymal programs. Consistently, NECTIN4-high basal/squamous muscle-invasive BCs showed favorable survival, higher checkpoint inhibitor response rates, and a coordinated CD8+ T cell-inflamed microenvironment with no comparable associations in luminal papillary tumors. In orthotopic models, murine Nectin4 promoted CD8+ T cell-dependent tumor control, whereas human NECTIN4 conferred EV sensitivity. EV also attenuated NECTIN4-dependent TIGIT binding. Conversely, NECTIN4-low models were preferentially sensitive to HDAC inhibition. NECTIN4 therefore couples antibody-drug conjugate targetability to a subtype-specific tumor–immune state permissive for checkpoint blockade, whereas the NECTIN4-low state defines a distinct inflammatory-mesenchymal state with an alternative therapeutic vulnerability. eTOC blurb: Nishimura et al. show that NECTIN4, the target of enfortumab vedotin, defines subtype-dependent tumor–immune states in bladder cancer. In basal/squamous tumors, NECTIN4 restrains inflammatory-mesenchymal programs and marks a CD8-rich microenvironment linked to checkpoint inhibitor response, whereas NECTIN4-low models show preferential sensitivity to HDAC inhibition. HIGHLIGHTS: NECTIN4 is a subtype-dependent regulator of tumor state, not just an ADC target NECTIN4-high Ba/Sq tumors exhibit a coordinated CD8-inflamed microenvironment Nectin4 drives CD8 T cell-dependent tumor control in immunocompetent mice NECTIN4 couples EV targetability to a checkpoint-responsive immune context
- Open Access
- 1 August 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (8)
Over 20-Year Outcomes of a Bladder-Preserving Multimodal Strategy Using Balloon-Occluded Intraarterial Infusion (AZUMA Regimen) in 1,701 Patients With High-Risk and Locally Advanced Bladder Cancer
Purpose: We evaluated long-term oncologic outcomes, including cancer-specific survival, of a bladder-preserving multimodal strategy (AZUMA regimen) combining balloon-occluded arterial infusion, radiotherapy, and hemodialysis in patients with high-risk and locally advanced bladder cancer. Materials and Methods: Between 1988 and 2025, 1701 patients with bacillus Calmette–Guérin-refractory carcinoma in situ, T1 disease, or muscle-invasive bladder cancer (T2–T4) without distant metastasis were treated with the AZUMA regimen. Treatment response, recurrence, overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) were analyzed. Prognostic factors were evaluated using logistic regression and Cox proportional hazards models. Results: Complete response was achieved in 1432 patients (84.2%). The median follow-up was 366 weeks. Among complete responders, 78.1% preserved a functional bladder without recurrence. The 5-, 10-, and 15-year OS rates were 80.5%, 73.9%, and 63.3%, and the corresponding 5-, 10-, and 15-year PFS rates were 70.8%, 65.5%, and 56.2%, respectively. After excluding non–cancer-related deaths, the 5-, 10-, 15-, and 20-year CSS rates were 84.4%, 81.9%, 80.3%, and 80.3%, respectively. Lymph node involvement, T4 disease, and nonurothelial carcinoma histology were independently associated with inferior outcomes. Among node-positive patients, 70.2% achieved complete response, and the 15-year CSS rate was 57.9%. Outcomes were particularly favorable in N1 disease, with a 15-year CSS of 72.9%. Grade IV toxicity was not observed. Conclusions: The AZUMA regimen was associated with durable cancer control and high rates of bladder preservation with acceptable toxicity, supporting its consideration as a bladder-preserving option in selected patients with advanced bladder cancer.
- 1 August 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (8)
Open AccessOver 20-Year Outcomes of a Bladder-Preserving Multimodal Strategy Using Balloon-Occluded Intraarterial Infusion (AZUMA Regimen) in 1,701 Patients With High-Risk and Locally Advanced Bladder Cancer
Purpose: We evaluated long-term oncologic outcomes, including cancer-specific survival, of a bladder-preserving multimodal strategy (AZUMA regimen) combining balloon-occluded arterial infusion, radiotherapy, and hemodialysis in patients with high-risk and locally advanced bladder cancer. Materials and Methods: Between 1988 and 2025, 1701 patients with bacillus Calmette–Guérin-refractory carcinoma in situ, T1 disease, or muscle-invasive bladder cancer (T2–T4) without distant metastasis were treated with the AZUMA regimen. Treatment response, recurrence, overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) were analyzed. Prognostic factors were evaluated using logistic regression and Cox proportional hazards models. Results: Complete response was achieved in 1432 patients (84.2%). The median follow-up was 366 weeks. Among complete responders, 78.1% preserved a functional bladder without recurrence. The 5-, 10-, and 15-year OS rates were 80.5%, 73.9%, and 63.3%, and the corresponding 5-, 10-, and 15-year PFS rates were 70.8%, 65.5%, and 56.2%, respectively. After excluding non–cancer-related deaths, the 5-, 10-, 15-, and 20-year CSS rates were 84.4%, 81.9%, 80.3%, and 80.3%, respectively. Lymph node involvement, T4 disease, and nonurothelial carcinoma histology were independently associated with inferior outcomes. Among node-positive patients, 70.2% achieved complete response, and the 15-year CSS rate was 57.9%. Outcomes were particularly favorable in N1 disease, with a 15-year CSS of 72.9%. Grade IV toxicity was not observed. Conclusions: The AZUMA regimen was associated with durable cancer control and high rates of bladder preservation with acceptable toxicity, supporting its consideration as a bladder-preserving option in selected patients with advanced bladder cancer.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S5 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma
Table S1, Table S2, Table S3, Table S4, Table S5
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S5 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma
Table S1, Table S2, Table S3, Table S4, Table S5
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Transplantation
- Vol. 2026 (1)
Living Kidney Transplantation in a Patient With End‐Stage Kidney Disease Due to Rare Juvenile Nail‐Patella‐Like Renal Disease Without LMX1B Mutation
Nail‐patella syndrome (NPS) is a rare disease characterized by fingernail dysplasia, patellar dysplasia, elbow deformities, and iliac horns, with a prevalence of 1 in 50,000 children. Most cases are caused by LMX1B mutations. Approximately 10%–40% of patients with NPS develop renal dysfunction in early childhood, whereas approximately 30% progress to end‐stage renal disease (ESRD). In addition, a few reports describe NPS without LMX1B mutations, but the mechanism affecting renal function is still unclear. In particular, nail‐patella‐like renal disease (NPLRD) presents solely with nephropathy without the physical changes that are characteristic of NPS. Herein, we report a case of clinicopathological NPLRD with characteristic NPS findings on electron microscopy but without physical features or LMX1B mutation, as confirmed by whole exome sequencing. The patient subsequently progressed to ESRD and underwent living‐related kidney transplantation. Seven years posttransplantation, no renal function‐related events occurred, and the patient returned to social activities without complications.
- 1 January 2026
- Published by Wiley in Case Reports in Transplantation
- Vol. 2026 (1)
Open AccessLiving Kidney Transplantation in a Patient With End‐Stage Kidney Disease Due to Rare Juvenile Nail‐Patella‐Like Renal Disease Without LMX1B Mutation
Nail‐patella syndrome (NPS) is a rare disease characterized by fingernail dysplasia, patellar dysplasia, elbow deformities, and iliac horns, with a prevalence of 1 in 50,000 children. Most cases are caused by LMX1B mutations. Approximately 10%–40% of patients with NPS develop renal dysfunction in early childhood, whereas approximately 30% progress to end‐stage renal disease (ESRD). In addition, a few reports describe NPS without LMX1B mutations, but the mechanism affecting renal function is still unclear. In particular, nail‐patella‐like renal disease (NPLRD) presents solely with nephropathy without the physical changes that are characteristic of NPS. Herein, we report a case of clinicopathological NPLRD with characteristic NPS findings on electron microscopy but without physical features or LMX1B mutation, as confirmed by whole exome sequencing. The patient subsequently progressed to ESRD and underwent living‐related kidney transplantation. Seven years posttransplantation, no renal function‐related events occurred, and the patient returned to social activities without complications.
- Open Access
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma
Outcome = Positive: CR or PR; Negative: SD or PD. a AUC (95% CI): 0.656 (0.441, 0.870), with the cutoff value based on a Youden Index of 99 (sensitivity: 0.583, specificity: 0.826). b AUC (95% CI): 0.524 (0.324, 0.724), with the cutoff value based on a Youden Index of 50% (sensitivity: 0.417, specificity: 0.739). c AUC (95% CI): 0.580 (0.365, 0.795), with the cutoff value based on a Youden Index of 1380.27 (/μL) (sensitivity: 0.583, specificity: 0.750). AUC, area under the curve; CR, complete response; PD, progressive disease; PD-L1, programmed death-ligand 1; PR, partial response; SD, stable disease.
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma
Outcome = Positive: CR or PR; Negative: SD or PD. a AUC (95% CI): 0.656 (0.441, 0.870), with the cutoff value based on a Youden Index of 99 (sensitivity: 0.583, specificity: 0.826). b AUC (95% CI): 0.524 (0.324, 0.724), with the cutoff value based on a Youden Index of 50% (sensitivity: 0.417, specificity: 0.739). c AUC (95% CI): 0.580 (0.365, 0.795), with the cutoff value based on a Youden Index of 1380.27 (/μL) (sensitivity: 0.583, specificity: 0.750). AUC, area under the curve; CR, complete response; PD, progressive disease; PD-L1, programmed death-ligand 1; PR, partial response; SD, stable disease.
- Open Access
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S5 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma
Table S1, Table S2, Table S3, Table S4, Table S5
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S5 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma
Table S1, Table S2, Table S3, Table S4, Table S5